Evogene Schedules First Quarter 2026 Financial Results Release
Rhea-AI Summary
Evogene (NASDAQ: EVGN) will release its Q1 2026 financial results on Wednesday, May 20, 2026. Management will host a live Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel). Registration is required: https://www.veidan-conferencing.com/evogene. A replay will be posted on the company's website a few days after the call.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows target flagged as down while peers are mixed: ERNA up 18.05%, BRTX down 4.0%. This pattern supports a stock-specific setup rather than a broad biotech move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Earnings results | Negative | -6.2% | Reported 2025 results with continued operating and net losses plus restructuring. |
| Feb 19 | Earnings scheduling | Neutral | -5.6% | Announced date and call details for Q4 and full-year 2025 results. |
| Nov 06 | Earnings scheduling | Neutral | -1.7% | Set timetable and Zoom call for Q3 2025 financial results release. |
| Aug 19 | Earnings results | Neutral | -4.2% | Reported Q2 2025 results with higher H1 revenue and lower expenses amid restructuring. |
| Jul 29 | Earnings scheduling | Neutral | -2.3% | Announced Q2 2025 results date and investor conference call logistics. |
Earnings-related announcements have often coincided with negative next-day moves, even when merely scheduling results.
Over the past year, Evogene’s earnings-related news has generally been followed by modest declines. Actual results on Mar 5, 2026 saw a -6.16% reaction amid ongoing losses and restructuring. Prior result releases and scheduling notices in 2025–2026 around Q2, Q3, and full-year updates produced single‑day moves between roughly -1.69% and -5.57%. Today’s Q1 2026 scheduling fits this pattern of frequent financial updates against a challenging operating backdrop.
Historical Comparison
In the past year, Evogene’s five earnings-related announcements saw an average move of about -4%, with both result releases and simple scheduling notices often followed by modest declines.
Earnings updates trace Evogene’s transformation, showing repeated cost-cutting, asset sales and strategic focus on ChemPass AI, while scheduling releases maintain regular visibility around quarterly and annual results.
Regulatory & Risk Context
An effective F-3 dated Mar 26, 2026 registers 5,076,924 ordinary shares for resale linked to warrants. If exercised in full for cash, Evogene would receive $6.35 million, and the resale registration facilitates secondary sales that could add to share overhang.
Market Pulse Summary
This announcement sets the timetable for Evogene’s Q1 2026 financial results and investor call, continuing a pattern of frequent earnings communications. Historically, similar earnings-related news produced an average move of about -4%. Recent filings highlight operating losses of $14.0M in 2025 and going-concern risk, alongside an effective F-3 covering 5,076,924 warrant-linked shares. Upcoming results, liquidity plans, and any updates on warrant exercises are key metrics to watch.
AI-generated analysis. Not financial advice.
Zoom conference call scheduled for May 20, 2026, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.
At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Contact
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-first-quarter-2026-financial-results-release-302765447.html
SOURCE Evogene